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Abstract Rationale: Methylphenidate (MPH) is widely
used in the treatment of attention deficit hyperactivity
disorder (ADHD) and is associated with positive clinical
effects across a wide range of domains. Despite the clinical
effectiveness of MPH, concern has arisen with respect to
its abuse potential. Objectives: To assess MPH prefer-
ence in adults diagnosed with ADHD using a choice
procedure and to evaluate the relationship among drug
preference, therapeutic efficacy, and abuse potential in a
clinical sample. Methods: Participants were ten volun-
teers (ages 18–22 years) with ADHD who were receiving
MPH treatment. Preference was assessed using a double-
blind choice procedure with four sampling sessions
wherein subjects received either placebo or MPH and
eight choice sessions when they chose either capsule or no
capsules. Results: Overall, MPH was chosen signifi-
cantly more often than placebo (χ2=52.5; P<0.001) and
participants were equally separated into groups of those
who chose MPH reliably (MPH choosers) and those who
did not (MPH non-choosers). MPH decreased ADHD
symptoms and resulted in lower ratings of stimulant
effects among MPH choosers. MPH choosers also
reported higher levels of baseline ADHD symptoms.
Conclusions: Despite higher preference of MPH than
placebo in this clinical sample, other measures of abuse
potential were not elevated, and MPH choosers were more
symptomatic than non-choosers. As such, MPH preference
in ADHD populations likely reflects therapeutic efficacy
rather than abuse potential. Future work should examine
MPH choice in diagnosed and non-diagnosed populations
to further explore the role of clinical efficacy in the
preference of this stimulant drug.
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Introduction
Attention deficit hyperactivity disorder (ADHD) function-
ally impairs 3–5% of the school-age population (American
Psychiatric Association 1994), and the persistence of
ADHD into adolescence and adulthood has been widely
supported (Barkley 1990; Biederman et al. 1993; Gittel-
man et al. 1985; Wilens et al. 1995). Most individuals with
ADHD receive pharmacological treatment, and the
majority of products prescribed for ADHD are methyl-
phenidate (MPH) based (Robinson et al. 1999; Zarin et al.
1998; Zito et al. 2000). In children with ADHD, MPH-
based products have positive effects across a wide range of
domains (DuPaul et al. 1998; Greenhill 1998). Similarly,
in adults diagnosed with ADHD, MPH is associated with
improvements in attention span, behavior, cognitive
aptitude, memory processing, mood stability, and senso-
rimotor coordination (Faraone et al. 2004; Spencer et al.
1995).
Despite the clinical effectiveness of MPH, concern has
arisen with respect to its abuse potential (see Kollins et al.
2001 for review; Drug Enforcement Administration 2000;
Llana and Crismon 1999; Safer 2000; Safer et al. 1996;
Popper 1995). For example, in a survey of school-aged
children, one of six reported having been approached to
buy, sell, or trade MPH (Musser et al. 1998). MPH misuse
has also been reported in adolescents in outpatient
substance-abuse treatment programs, and in non-clinical
samples of college students (Babcock and Bryne 2000;
Marsh et al. 2000). Case reports document more clinically
significant patterns of MPH misuse, with users taking the
drug to induce euphoria by crushing the tablet and
administering it intranasally or intravenously (Fulton and
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Yates 1988; Jaffe 1991; Parran and Jasinski 1991). Thus,
the misuse and diversion of MPH has been documented
and may be increasing.
In addition to survey-based research, laboratory studies
suggest that MPH functions behaviorally like other
stimulant drugs of abuse, such as d-amphetamine and
cocaine, in non-humans and humans. In relation to these
other stimulants, MPH produces comparable discrimina-
tive stimulus, subjective, and reinforcing effects (Kollins
2003; Kollins et al. 2001).
Traditionally, the reinforcing effects of a drug are
considered to be one of the most powerful predictors of
abuse because of the face valid nature of the assays used to
assess these effects and because of the close correspon-
dence between reinforcing effects and other measures of
abuse potential (Balster and Bigelow 2003; Fischman
1989). To date, however, only four published studies have
directly examined the reinforcing effects of MPH in
humans and results have been mixed. Two studies
assessed the reinforcing effects of MPH using a choice
procedure in healthy adult participants. One of these
reported that MPH was chosen on only 27.6% of choices,
compared with 8.6% for placebo and 63.8% for no
capsules at all (Chait 1994); while the other study reported
that 10 mg MPH was reliably chosen more often than
placebo, but only when participants were sleep deprived
(Roehrs et al. 1999). Two additional studies reported that
MPH administered either orally or intranasally produced
dose-dependent reinforcing effects in healthy adults using
two different assays (progressive ratio procedure, Rush et
al. 2001; multiple choice procedure, Stoops et al. 2003).
No studies have experimentally assessed the abuse
potential of MPH in individuals with ADHD who are
prescribed the drug for clinical purposes. In fact, only a
few studies have examined the reinforcing effects of
psychoactive drugs in individuals who receive them for
clinical purposes. For example, the reinforcing effects of
diazepam and alprazolam—sedatives which have clearly
demonstrated abuse potential in non-clinical samples
(Gomez et al. 2002; Juergens 1991; Woods and Winger
1995)—have been examined in individuals diagnosed with
varying levels of clinically significant anxiety (McCracken
et al. 1990; Roache et al. 1997; deWit et al. 1986). In one
study, volunteers with either generalized anxiety disorder
or panic disorder preferred alprazolam significantly more
than placebo under free-choice, double-blind conditions,
which by definition suggested reinforcing effects. The
patterns of self-administration and subjective effects,
however, were not suggestive of misuse or abuse potential
in this study (Roache et al. 1997). The implication of this
study is that, in clinical samples, the reinforcing effects of
a drug may be more associated with therapeutic efficacy
than with the potential for abuse, and that the examination
of both subjective effects and reinforcing effects is
necessary to make this important distinction.
In the past decade, the therapeutic use of MPH has
increased, leading to debates surrounding the prescription
rates and safety of this stimulant drug (Rappley 1997).
Critics argue that MPH is overprescribed (see Safer 2000
for a discussion) and that early stimulant treatment
predisposes individuals with ADHD to develop problems
with substance abuse (Lambert and Hartsough 1998).
Although mounting evidence suggests the opposite to be
true (i.e., that stimulant treatment for ADHD serves a
protective function for the development of substance use
disorders; Wilens et al. 2003), the reinforcing effects of
MPH have yet to be studied in a sample of patients for
whom the medication is known to have clinical benefits.
The purpose of the present study was to examine MPH
preference and participant-rated effects in adults diagnosed
with ADHD so as to more clearly distinguish the drug’s
therapeutic efficacy from its abuse potential in this clinical
sample to whom it is most commonly administered.
Materials and methods
Participants
Participants in this study were seven males and three females (ages
18–22 years). The participants were recruited through local
physicians and psychologists, recruitment flyers, and word of
mouth on the basis of two criteria: (a) an established diagnosis of
ADHD and (b) a current prescription for MPH for the treatment of
symptoms associated with ADHD. All participants had been
receiving MPH treatment for at least 6 months prior to selection
for the study. At the time of the study, all subjects were receiving
immediate-release MPH. One subject had been on an extended
release formulation several years prior to the study, but had been on
immediate-release MPH for the 6 months prior to the study.
To corroborate the ADHD diagnostic status of participants and to
ensure a homogeneous group, participants were required to receive a
score of 36 or higher on the Wender Utah rating scale (WURS; Ward
et al. 1993) and obtain a T score of 65 or higher on the ADHD
symptoms scale of the Conners Adult ADHD Rating Scale
(CAARS; Conners et al. 1999b). Patients were instructed to
complete the questionnaires based on their behavior when they
were not on their medication. Both of these instruments have been
shown to have adequate psychometric properties and have good
predictive validity at identifying adults who meet full criteria for
ADHD (Conners et al. 1999a; McCann et al. 2000; Stein et al. 1995;
Ward et al. 1993). In addition, all volunteers had been previously
diagnosed by pediatricians, family physicians and/or counselors, and
had been receiving stimulant medication for years. The primary care
physicians for each volunteer also reviewed the protocol and
approved their participation.
Participants were excluded if they were taking any other type of
psychoactive medication, exhibited any gross neurological, sensory
or motor impairment, had a history of other significant learning or
psychiatric problems, or any current severe psychiatric disturbances
(e.g., suicidality, homicidality, criminality). A total of 17 individuals
were screened and seven were excluded for the following reasons:
not currently receiving MPH treatment (four participants), not
willing to receive placebo (two participants), did not meet inclusion
criteria on the CAARS (one participant). The ten individuals who
completed the study had a mean CAARS ADHD total subscale T
score of 77.9 (range 67–90), a mean WURS total score of 54.6
(range 36–63), and were receiving a mean maintenance dose of
16.5 mg MPH (range 10–30 mg).
Participants received monetary compensation for their participa-
tion in the 13 sessions. Participants received US $5 for each session
and an additional US $20 for completing all 13 sessions. In addition,
by returning their daily questionnaires, participants were entered
into weekly drawings for the opportunity to win gift certificates and
coupons to local businesses and restaurants. The Human Subjects




Volunteers participated in 13 sessions. The first session was a
screening session wherein the participant completed self-report
assessment measures. In addition, medical history, comorbid mental
health diagnoses, length of time on MPH, and dosing information
were obtained. None of the participants reported comorbid psychi-
atric diagnoses.
Each participant’s maintenance dose of MPH and an inert placebo
were administered in opaque capsules (size 01). Placebo and MPH
capsules were placed in separate bottles labeled as “Bottle A” and
“Bottle B.” Participants were instructed that they would receive
either their typical dose of MPH or placebo throughout the
experiment. They were also instructed that, after taking their
capsules, they would be free to leave the laboratory and resume their
daily activities. Participants were instructed to complete question-
naires provided to them, 1.5 h and 4 h after leaving the laboratory, to
be returned by the end of the day. During sampling sessions,
participants were provided one capsule of either MPH or placebo.
During choice sessions, participants were presented with both MPH
and placebo capsules—along with a choice of no capsules—and
were instructed to select one of the three possible options.
For experimental sessions, participants were asked to maintain
their normal caffeine and nicotine use and to refrain from eating 1 h
before the session. In addition, participants were asked to refrain
from taking their MPH prescription for at least 4 h prior to coming
into the laboratory. In general, participants chose to schedule their
sessions first thing in the morning, so they refrained from taking
their first dose of MPH until they arrived at the session. The 4-h
restriction on their medication administration did not deviate
significantly from their typical medication regimen.
There were three sessions each week for 4 weeks. The methods
used in the present study are modeled after similar drug preference
studies (Chait et al. 1987; deWit et al. 1984; Johanson et al. 1983;
Johanson and Uhlenhuth 1982).
Sampling sessions
The first four sessions were sampling sessions. The sampling
sessions were designed to allow participants to experience the
effects of the two drug conditions (MPH and placebo) on the basis
of which they would subsequently make their drug choice.
On the first sampling day, upon arriving at the laboratory,
participants were given a standard light snack (juice and breakfast
bar). Participants then completed the participant-rated effects scale
(PRES). During the first sampling session, after completing the
participant-rated effects questionnaire, participants received either
placebo or MPH in a capsule labeled “Pill A” or “Pill B.” In the
second sampling session, participants received the other substance
in a capsule labeled with the other letter. Participants also received a
card labeled with the same letter as the pill administered as a
reminder of which capsule they received that day. Participants were
instructed to associate the effects of the capsule with its letter label.
Capsule letter assignments varied across participants, and the order
in which placebo and MPH were scheduled in the sampling sessions
was counterbalanced across subjects and within subjects across
weeks. The third and fourth sampling sessions followed the same
capsule administration order.
After receiving the capsule, the participants were free to leave the
laboratory and resume daily activities. Previous studies examining
the reinforcing effects of drugs in clinical samples have used similar
outpatient procedures whereby the participants make their drug
choices in the context of their everyday lives (Roache et al. 1997).
Volunteers were given two questionnaire packets and were
instructed to complete them in 1.5 h and 4 h following capsule
ingestion. Because these participants had demanding class and work
schedules, in addition to being diagnosed with ADHD, they were
asked to complete questionnaires only twice post-drug administra-
tion so as to minimize interference with their daily functioning.
Participants were required to return their packets to the laboratory by
1700 hours, at which time they received their ticket for the weekly
drawings. To increase compliance, participants were asked to record
the time of questionnaire completion and were required to return the
questionnaires to the lab 4 h post-drug administration.
Choice sessions
The remaining eight sessions were choice sessions. In the choice
sessions, following the completion of questionnaires, participants
were presented three cups for the drug choice administration: one
labeled “Pill A” (or whatever letter corresponded to MPH), one
labeled “Pill B” (or whatever letter corresponded to placebo), and an
empty cup labeled “C.” The participant chose either to ingest “Pill
A,” to ingest “Pill B,” or to take neither capsule. The use of a
“neither” option was included to replicate prior studies of the
reinforcing effects of MPH (Chait 1994) and to provide a more
reliable measure of the reinforcing efficacy of the chosen substance
(Spiga and Roache 1997). This choice procedure is a technique that
has been used to measure the reinforcing effects of a number of
different drugs, in a range of contexts and with various subject
populations (deWit and Griffiths 1991; Foltin and Fischman 1991;
Johanson and deWit 1989). Following each choice, the participant
was presented with the appropriate letter-matched card. After
capsule administration, the participant was free to leave the
laboratory and resume daily activities. The procedures for collecting




Drug choice was the primary measure of drug preference. The
number of times one option (MPH, placebo, neither) was chosen
over the other served as an indicator of its relative reinforcing
effects.
Participant-rated effects
The participant-rated effects were assessed pre-drug administration,
1.5 h and 4 h post-drug administration. The participant-rated effects
measures are as follows.
Participant-rated effects scale (PRES) The PRES is a 25-item scale
developed for this study to assess the subjective effects of MPH in
adults diagnosed with ADHD. Items on this form were derived from
four primary sources: Addiction Research Center Inventory (ARCI;
Martin et al. 1971), Profile of Mood States (POMS, McNair et al.
1971), CAARS (Conners et al. 1999b), and the DSM-IV (American
Psychiatric Association 1994). Items included those that had been
used to measure the participant-rated effects of many drugs and are
sensitive to the effects of stimulants (Heishman and Henningfield
1991). The items from the CAARS and the DSM-IV included
symptoms of ADHD and were selected because of clinical utility in
determining the effects of stimulant medications in this population.
Items from the questionnaire were rated on a five-point scale (1–
5), where each numeric value corresponded to a phrase describing
the frequency or intensity of the item (1, not at all; 2, a little bit; 3,
moderately; 4, quite a bit; 5, extremely). Participants were instructed
to rate each item according to how they felt “at that moment.”
End of the day questionnaire This five-item questionnaire was
administered approximately 4 h after capsule ingestion to measure
the overall effect of the drug received. Participants rated “drug
strength,” “drug liking,” “good effects,” “bad effects,” and “like to
take again” on a five-point scale (0, not at all; 1, a little bit; 2,
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moderately; 3, quite a bit; 4, very much). Participants were also
prompted to provide reasons for their pill choice, and to report any
untoward drug effects.
Perceived effectiveness Participants were asked prior to the study to
rate how effective their current prescription of MPH was for them.
Ratings were made on a five-point scale that was anchored with the
points 1=“not effective” and 5=“extremely effective.”
Data analysis
Drug preference The number of times MPH, placebo, and neither
were chosen were taken as indicators of participant drug preference
and can be conceptualized as an index of the drug’s positive
reinforcing properties (deWit et al. 1984). The reinforcing effects of
MPH were assessed by calculating the total number of choices of
MPH, placebo, and neither across participants and examining the
proportion of choices with a chi-square analysis. “Choosers” were
defined as individuals who selected MPH on at least five of eight
occasions. Choice patterns among “MPH choosers” and “non-
choosers” were analyzed using independent t-tests.
Participant-rated effects The participant-rated effects were analyzed
by transforming the 25-item questionnaire into three rationally
derived composite scores: ADHD composite (10 items: unable to
concentrate, focused*, forgetful, talkative, fidgety, distracted, rest-
less, impulsive, overactive, inattentive), mood composite (12 items:
happy*, anxious, tense, angry, sad, fatigued, annoyed, cheerful*,
nervous, agitated, irritable, frustrated), and stimulant composite (3
items: hungry*, energetic, excited). The composite scores were
averaged for each subject at each of the three time periods (pre,
1.5 h, 4 h). Separate averages were calculated for MPH and placebo
sampling sessions, as well as for each of the three choices (MPH,
placebo, neither) for choice sessions. Because participants were not
exposed to the same number of MPH, placebo, and no-drug days,
data from the choice days were not analyzed statistically (items
marked with an asterisk were reverse scored).
Independent t-tests were used to assess the differences between
subsequent MPH choosers and non-choosers with respect to pre-
drug ADHD, mood, and stimulant composite scores. Pre-adminis-
tration scores for both choosers and non-choosers were averaged
across MPH and placebo sampling sessions to obtain a single
baseline measure for each participant-rated effect composite. Data
from the sampling sessions were also analyzed using a two-way
analysis of variance (time×group) to compare the participant-rated
effects obtained by MPH choosers and non-choosers prior to MPH
administration and 1.5 h after administration. The end of day
questionnaire ratings were analyzed using paired t-tests to compare
ratings on each item following MPH and placebo across all sessions
and separately across sampling and choice sessions. Given the small
sample size and the exploratory nature of this study, we did not
correct statistically for the multiple comparisons conducted and
results should therefore be interpreted with caution.
Results
Reinforcing effects
The results of the choice sessions were analyzed by
examining the percentage of MPH choices per subject
(Fig. 1). Of 80 total choices across all participants (8
choices each), MPH was chosen 40 times (50%), placebo
was chosen 26 times (32.5%), and neither was chosen 14
times (17.5%). A chi-square analysis found that the
number of choices of MPH, placebo, and neither differed
significantly (χ2=52.5, P<0.001).
According to the criteria used by Chait (1994),
participants 1, 3, 6, 7, and 10—on the experimental
doses of 10 mg, 20 mg, 30 mg, 10 mg, and 20 mg,
respectively—were classified as “MPH choosers.” The
remaining participants were classified as “non-choosers.”
Specifically, participants 2, 5, and 8—on experimental
doses of 10 mg, 20 mg, and 10 mg, respectively—chose
placebo more often than MPH, and participants 4
(experimental dose 20 mg) and 9 (experimental dose
20 mg) did not demonstrate reliable choice patterns
(Fig. 2). Participants classified as choosers or non-
choosers, however, still did not exhibit exclusive choice
for one substance. MPH choosers selected MPH sig-
nificantly more often than non-choosers (mean MPH
choices for choosers=6.2, mean for non-choosers=1.8;
t=5.0, P=0.001). Conversely, MPH choosers chose place-
bo significantly less often than non-choosers (mean
placebo choices for choosers=0.6, mean for non-choo-
sers=4.6; t=−3.6, P=0.007). There were no significant
differences between MPH choosers and non-choosers with
respect to choices of neither.
Participant-rated effects
An analysis of pre-drug scores revealed significant
differences between non-choosers and MPH choosers
only on the stimulant-effects composite (mean for
choosers=8.35, mean for non-choosers=6.25; t=2.7,
P=0.03).
Results from the two-way ANOVA also revealed a
significant interaction (time×group) for the ADHD
composite scores (F1,8=9.0, P=0.017). There was a trend
toward a significant interaction (time×group) for the
stimulant drug effects (F1,8=4.8, P=0.059), which likely
results from the decrease in effects among MPH choosers.
These effects are depicted graphically in Fig. 3.These
results suggest that participants who reliably chose MPH
reported a significant decrease in ADHD symptoms and a
trend toward a significant decrease in stimulant drug
Fig. 1 Percentage of choices for methylphenidate (MPH), placebo,
and neither across all participants (N=10). Asterisk indicates that the
total number of MPH choices across participants was significantly
different from choices of placebo and neither (χ2=52.5, P<0.001)
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effects during sampling sessions, while non-choosers did
not report reliable changes across sampling sessions.
Specifically, participants who experienced a significant
reduction in ADHD symptoms during sampling sessions
were more likely to select MPH during choice sessions.
Moreover, MPH choosers reported significantly higher
ratings of perceived effectiveness of their MPH than non-
choosers prior to the study (mean for choosers=4.8/5.0,
mean for non-choosers=3.2/5.0; t=1.9, P=0.04).
Discussion
The results demonstrate that, as a group, adults with
ADHD chose to take MPH significantly more frequently
than they chose to take either placebo or no capsules.
Within the group, however, clear patterns of preference
were evident. Half of the sample chose MPH more
frequently than the other two options, and this pattern of
preference was related to therapeutic efficacy as measured
by reduction in ADHD symptoms following administra-
tion of the drug. The other half of participants who did not
choose to take MPH exhibited lower levels of baseline
ADHD symptoms and reported lower baseline efficacy of
their prescribed dose.
Whereas drug reinforcement measured by choice
procedures is often interpreted as being indicative of a
drug’s abuse potential (deWit and Johanson 1987), the
present study lends support for the notion that, in clinical
samples, drug preference may instead be associated with
clinical efficacy. Examination of the patterns of drug
preference alongside participant-rated effects shows
clearly that MPH decreased ADHD symptoms without
significant concomitant changes in either mood effects or
stimulant-like effects. Moreover, clinically diagnosed
individuals for whom ADHD symptoms were not impact-
ed by MPH chose not to self-administer the drug reliably.
These findings are comparable with those reported
previously with anxious patients who reliably chose to
self-administer alprazolam, but not in a manner indicative
of abuse potential (Roache et al. 1997). Compared with
other human studies of MPH preference, the results of this
experiment may be most similar to Roehrs et al. (1999) in
that the reinforcing effects of MPH may be context
specific. As the reinforcing effects of MPH were
associated with the contextual variable of sleep depriva-
tion (Roehrs et al. 1999), the reinforcing effects of MPH in
the present study may be associated with contextual
variables of attentional disturbances (severity of ADHD
symptoms). Indeed, results suggest that, during sampling
sessions, MPH choosers exhibited a greater reduction in
ADHD symptoms following MPH administration.
Although during sampling sessions the non-choosers
reported mild reduction in ADHD symptoms following
Fig. 2 Individual patterns of methylphenidate (MPH) preference for
all subjects. MPH choosers were those selecting MPH five or more
times (Chait 1994). Figures inside bars represent subject numbers
and dose of MPH used to assess preference
Fig. 3 Participant-rated effects for methylphenidate (MPH) choo-
sers and non-choosers for the three rationally derived participant-
rated effects composites. Data were drawn from sampling sessions
and represent averages at pre-drug and 1.5 h after MPH
administration. † Significant effect of time: F1,8=16.7, P=0.03; §
significant effect of time×group: F1,8=9.0, P=0.01; * significant
effect of group: F1,8=5.7, P=0.04; ¶ significant effect of time:
F1,8=30.3, P=0.001
395
MPH, these changes were not significant. This suggests
that the reinforcing effects of MPH are related to the
clinical efficacy of MPH such that the more effective MPH
was in reducing ADHD symptoms, the more likely it was
chosen over placebo. Of note, the CAARS and WURS
scores at screening did not differ between choosers and
non-choosers, indicating that the groups were not different
from a clinical standpoint, but rather in how their ADHD
symptoms were impacted by MPH administration.
This study has several important implications. First, it
adds to a sparse literature on the reinforcing effects of
MPH in humans and is the first to study these effects in a
sample of individuals receiving the drug for clinical
purposes. Previous studies have reported discrepant
results. One study failed to report consistent reinforcing
effects (Chait 1994); one study reported reinforcing effects
under specific conditions of sleep deprivation (Roehrs et
al. 1999); and two studies reported significant reinforcing
effects relative to placebo (Rush et al. 2001; Stoops et al.
2003).
Similar to the Roehrs et al. (1999) study wherein the
reinforcing effects of MPH were associated with condi-
tions of sleep deprivation, the reinforcing effects of MPH
in the present study may be associated with conditions of
distractibility, inattention or restlessness. For example,
anecdotal subject comments suggest that participants
chose MPH when they needed to study or had class.
Moreover, participants reported not choosing MPH when
they “wanted to take a nap” or “had nothing to do.”
Previous studies have demonstrated that the behavioral
requirements following drug administration (i.e., vigilance
or relaxation activities) can alter the self-administration of
stimulants (i.e., caffeine and d-amphetamine) and seda-
tives (i.e., triazolam) (Silverman et al. 1994a,b). Based on
these findings, the authors suggested that drug self-
administration is related to the changes in environmental
conditions. Thus, conditions of sleep deprivation, inatten-
tion and distractibility may function to increase the
reinforcing efficacy of MPH. Unfortunately, in this
study, the demands placed on participants following drug
choice were not experimentally manipulated. Previous
clinical research with children with ADHD has suggested
that response to MPH and other stimulants is impacted by
both child characteristics and the demands of the task
evaluated (Rapport et al. 1985). Subsequent research
would benefit from systematically addressing this issue
and determining whether MPH preference in individuals
with ADHD varies specifically as a function of subsequent
behavioral requirements.
Continued research examining the conditions associated
with MPH preference in clinical and non-clinical samples
will also be important from the standpoint of assessing the
abuse potential of MPH. The reinforcing effects of a
substance are typically used to assess the abuse potential
of that drug in human participants and it is widely
accepted that drug reinforcement is closely associated with
abuse liability (Fischman and Mello 1989). This study and
others (Roache et al. 1997), however, emphasize the need
to examine multiple endpoints (e.g., subjective effects and
reinforcing effects) in order to differentiate abuse potential
from therapeutic efficacy when psychoactive drugs are
examined in clinical samples.
Indeed, the reinforcing effects of a clinically used agent
may reflect therapeutic efficacy such that the choice of
drug over placebo may be negatively reinforced by the
consequences of eliminating aversive stimuli (e.g., anxi-
ety; Roache et al. 1997) or may be positively reinforced
with consequences such as being able to work more
efficiently, receiving greater praise from teachers and
peers, or getting better grades (as may be the case with
ADHD). Assessing drug preference along with clinically
relevant subjective effects as demonstrated in the present
study is one way to determine correlates of drug
preference and distinguish between abuse potential and
therapeutic efficacy.
Compared with non-choosers, MPH choosers in this
study reported more effectiveness of their medication
outside the context of the study. Non-choosers typically
reported relatively little benefit from their MPH dose and
preferred placebo significantly more often than MPH. Yet,
these individuals continue to take their prescribed medi-
cation despite the lack of clinical efficacy. This raises an
important issue regarding the variables that are maintain-
ing drug administration in these individuals. It may be the
case that the combination of drug-preference procedures
and assessment of clinically relevant subjective effects
could be used in clinical contexts to titrate patients to
optimal doses. Although MPH has been shown in
controlled trials to have clear benefits for adults (Faraone
et al. 2004), many primary caregivers are not familiar with
titration and medication management in adults with
ADHD. As such, procedures that can help these caregivers
identify optimal dosing strategies are needed in the field.
Also of note in these experiments is the characteristic
lack of subjective ratings of typical stimulant effects. A
number of other studies have demonstrated that orally
administered MPH as low as 20 mg results in significant
changes in ratings of “high” and other effects associated
with abuse potential (e.g., Heil et al. 2002; Kollins et al.
1998; Rush et al. 1998). Despite the reinforcing effects
reported in the present study, we found much more
variable stimulant-related subjective effects. Such results
suggest further that MPH may exert a differential profile
of abuse potential in individuals with ADHD compared
with non-diagnosed individuals.
Research suggests that neuropharmacological differ-
ences may contribute to differential abuse potential in
individuals diagnosed with ADHD relative to non-
diagnosed individuals. Evidence supports the idea that
neuropharmacological differences exist between diag-
nosed and non-diagnosed individuals with respect to
dopamine functioning. Specifically, individuals diagnosed
with ADHD differ from non-diagnosed controls with
respect to dopamine transporter (DAT) density (Dougherty
et al. 1999). These differences may contribute to the
expression of ADHD symptoms and the efficacy of MPH
treatment. Moreover, since individual differences in
dopamine functioning may also influence the abuse
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potential of MPH (Volkow et al. 1999, 2002), it stands to
reason that those differences observed in patients with
ADHD may be associated with a lower abuse potential of
MPH than non-diagnosed controls. Studies that directly
compare the abuse potential of MPH in groups of
individuals with and without ADHD are needed to further
explore this neuropharmacological hypothesis.
In general, the present experiment suggests that,
although MPH does produce reinforcing effects in
individuals with ADHD, these effects are more closely
associated with clinical efficacy than with abuse potential
of the drug. Subsequent research in this area should
compare the abuse potential of MPH and other clinically
used stimulants in samples of individuals with and without
ADHD, as well as manipulating the behavioral demands
following drug administration.
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